Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.60 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.60 |
| ▸ | LDHA | P00338 | 1/20 | 0.54 |
| ▸ | PPARG | P37231 | 3/20 | 0.53 |
| ▸ | KMO | O15229 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | FPR2 | P25090 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6674722 | 0.89 | KMO (0.57) | KMT2ABCL2L1MCL1PPARGKMO | |
| SCHEMBL3101828 | 0.88 | NPC1 (0.60) | KMT2ALDHAPPARGKMOPPARA | |
| SCHEMBL16284887 | 0.88 | NPC1 (0.60) | KMT2ALDHAPPARGKMOPPARA | |
| SCHEMBL16284888 | 0.88 | NPC1 (0.60) | KMT2ALDHAPPARGKMOPPARA | |
| SCHEMBL6672877 | 0.88 | NPC1 (0.60) | KMT2ALDHAPPARGKMOPPARA | |
| SCHEMBL11522651 | 0.87 | KMT2A (0.53) | KMT2ABCL2L1MCL1LDHAHPGD | |
| SCHEMBL3110072 | 0.87 | LDHA (0.54) | KMT2ABCL2L1MCL1LDHAPPARG | |
| SCHEMBL6671105 | 0.86 | KMO (0.54) | KMT2ABCL2L1MCL1PPARGKMO | |
| SCHEMBL3105307 | 0.84 | HPGD (0.54) | KMT2ALDHAPPARGHPGDALDH1A1 | |
| SCHEMBL9554501 | 0.83 | KMO (0.72) | BCL2L1MCL1PPARGKMOPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897644-B2 | Antiinflammatory agents; analgesics | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-03-01 | — | — | US | claimed |
| US-20100273872-A1 | USE OF 4-OXOBUTANOIC ACID DERIVATIVES IN THE TREATMENT OF PATHOLOGIES ASSOCIATED WITH IMMUNOLOGICAL DISORDERS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-10-28 | — | — | US | claimed |
| EP-2214659-A1 | USE OF 4-OXOBUTANOIC ACID DERIVATIVES IN THE TREATMENT OF PATHOLOGIES ASSOCIATED WITH IMMUNOLOGICAL DISORDERS | Merck Patent GmbH (DE) | 2010-08-11 | — | — | EP | claimed |
| WO-2009071161-A1 | USE OF 4-OXOBUTANOIC ACID DERIVATIVES IN THE TREATMENT OF PATHOLOGIES ASSOCIATED WITH IMMUNOLOGICAL DISORDERS | MERCK PATENT GMBH (DE) | 2009-06-11 | — | — | WO | claimed |
| EP-1450780-B1 | USE OF 4-OXOBUTANOIC ACID DERIVATIVES IN THE TREATMENT OF INFLAMMATION | MERCK PATENT GMBH (DE) | 2007-03-07 | — | — | EP | claimed |
| EP-1448181-B1 | PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF METFORMIN AND A 4-OXOBUTANOIC ACID, AND THE USE THEREOF FOR TREATING DIABETES | MERCK PATENT GMBH (DE) | 2006-05-31 | — | — | EP | claimed |
| CN-1633304-A | Pharmaceutical composition comprising an alpha-glucosidase inhibitor and a 4-oxobutanoic acid, and the use thereof for treating diabetes | MERCK PATENT GMBH (DE) | 2005-06-29 | — | — | CN | claimed |
| US-20050085489-A1 | Pharmaceutical composition comprising a glitazone and a 4-oxobutanoic acid, and the use thereof for treating diabetes | MERCK PATENT GMBH (DE) | 2005-04-21 | — | — | US | claimed |
| US-20050070553-A1 | Pharmaceutical composition comprising an alpha-glucosidase inhibitor and a 4-oxobutanoic acid, and the use thereof for treating diabetes | MERCK PATENT GMBH (DE) | 2005-03-31 | — | — | US | claimed |
| CN-1599608-A | Pharmaceutical composition comprising a glitazone and a 4-oxobutanoic acid, and the use thereof for treating diabetes | MERCK PATENT GMBH (DE) | 2005-03-23 | — | — | CN | claimed |
| CN-1592615-A | Pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for treating diabetes | MERCK PATENT GMBH (DE) | 2005-03-09 | — | — | CN | claimed |
| US-20050020609-A1 | Pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for treating diabetes | MERCK PATENT GMBH (DE) | 2005-01-27 | — | — | US | claimed |
| US-20050014768-A1 | Use of 4-oxobutanoic acid derivatives in the treatment of inflammation | MERCK PATENT GMBH (DE) | 2005-01-20 | — | — | US | claimed |
| EP-1463503-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLITAZONE AND A 4-OXOBUTANOIC ACID, AND THE USE THEREOF FOR TREATING DIABETES | MERCK PATENT GmbH (DE) | 2004-10-06 | — | — | EP | claimed |
| EP-1450780-A1 | USE OF 4-OXOBUTANOIC ACID DERIVATIVES IN THE TREATMENT OF INFLAMMATION | MERCK PATENT GmbH (DE) | 2004-09-01 | — | — | EP | claimed |
| WO-2003057216-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLITAZONE AND A 4-OXOBUTANOIC ACID, AND THE USE THEREOF FOR TREATING DIABETES | MERCK PATENT GMBH (DE) | 2003-07-17 | — | — | WO | claimed |
| WO-2003047574-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A DERIVATIVE OF 5-PHENOXYALKYL-2,4-THIAZOLIDINEDIONE TYPE AND A 4-OXOBUTANOIC ACID | MERCK PATENT GMBH (DE) | 2003-06-12 | — | — | WO | claimed |
| WO-2003047561-A1 | USE OF 4-OXOBUTANOIC ACID DERIVATIVES IN THE TREATMENT OF INFLAMMATION | MERCK PATENT GMBH (DE) | 2003-06-12 | — | — | WO | claimed |
| EP-0925273-B1 | PHARMACEUTICAL COMPOSITION CONTAINING 4-OXO-BUTYNIC ACIDS | MERCK PATENT GMBH (DE) | 2001-11-07 | — | — | EP | claimed |
| US-6143787-A | HETEROCYCLIC OR AROMATIC OXOACIDS | MERCK PATENT GESELLSCHAFT MIT (DE) | 2000-11-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020609-A1 | Pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for treating diabetes | GPR119, IAPP, SLC5A1 | KMT2A 3694/4885BCL2L1 3785/4885MCL1 3253/4885 |
| US-20100273872-A1 | USE OF 4-OXOBUTANOIC ACID DERIVATIVES IN THE TREATMENT OF PATHOLOGIES ASSOCIATED WITH IMMUNOLOGICAL DISORDERS | ABAT, HOGA1, IL4I1 | KMT2A 3283/4885BCL2L1 2758/4885MCL1 1125/4885 |
| US-20050070553-A1 | Pharmaceutical composition comprising an alpha-glucosidase inhibitor and a 4-oxobutanoic acid, and the use thereof for treating diabetes | GANAB, GAA, GANC | KMT2A 4137/4885BCL2L1 3694/4885MCL1 4851/4885 |
| US-20050014768-A1 | Use of 4-oxobutanoic acid derivatives in the treatment of inflammation | IL1B, HCAR2, IL6 | KMT2A 4052/4885BCL2L1 2298/4885MCL1 3948/4885 |
| US-20050085489-A1 | Pharmaceutical composition comprising a glitazone and a 4-oxobutanoic acid, and the use thereof for treating diabetes | SLC5A1, DPP4, SLC5A2 | KMT2A 2373/4885BCL2L1 3135/4885MCL1 4190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.